Tag: licensing
-
Novartis Gains Synthetic Protein Therapies for Covid-19
Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components.
-
Precision Drug Trial Shows Solid Tumor Shrinkage
Partial results from a clinical trial show a drug to stop specific cancer-causing proteins shrinks advanced tumors in some patients across several tumor types.
-
Roche Gains Covid-19 Oral Drug Candidate
Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a oral drug, rather than an infusion.
-
Gene Therapy Delivery Tech Licensed in $1.8B Deal
A biotechnology company creating synthetic viruses with artificial intelligence to deliver gene therapies is licensing its technology to drug maker Roche.
-
Start-Up Gains Access to Vaccine Nasal Spray Technology
A company developing techniques to deliver vaccines like Covid-19 with a nasal spray received an opportunity to license the process from University of Houston.
-
Start-Up Developing Thin Films for Vaccine Delivery
A new enterprise is creating thin films for vaccines, including Covid-19, to make possible their mass production and distribution at room temperatures.
-
Dexcom, UVirginia Partner on Diabetes Technology
Dexcom Inc., a maker of glucose monitoring systems, and University of Virginia are collaborating on extending the company’s current technologies to cover more types of diabetes
-
Univ Lab, Company Developing Phone-Based Virus Sensor
A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for detecting SARS-CoV-2 viruses by a smartphone camera.
-
DoD Funding Variable Covid-19 Vaccine Technology
The U.S. Department of Defense is funding work on a Covid-19 vaccine platform that can adjust its formula to protect against future mutations in the virus.
-
Sanofi Acquires Immune Disease Biotech in $3.7B Deal
A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi.